Zobrazeno 1 - 10
of 90
pro vyhledávání: '"ILHONG SON"'
Autor:
Dong Hwan Ho, Hyejung Kim, Daleum Nam, Mi Kyoung Seo, Sung Woo Park, Dong-Kyu Kim, Ilhong Son
Publikováno v:
NeuroSci, Vol 5, Iss 3, Pp 301-314 (2024)
Leucine-rich repeat kinase 2 (LRRK2) and α-synuclein are involved in the pathogenesis of Parkinson’s disease. The activity of LRRK2 in microglial cells is associated with neuroinflammation, and LRRK2 inhibitors are crucial for alleviating this neu
Externí odkaz:
https://doaj.org/article/e3d6090638ef442b8c176a26ff976812
Publikováno v:
Current Issues in Molecular Biology, Vol 46, Iss 5, Pp 4324-4336 (2024)
Astrocytes in the brain contribute to various essential functions, including maintenance of the neuronal framework, survival, communication, metabolic processes, and neurotransmitter levels. Leucine-rich repeat kinase 2 (LRRK2) is associated with the
Externí odkaz:
https://doaj.org/article/486c66daa0e54dc99c091cb975b46bdb
Autor:
Daleum Nam, Ami Kim, Sun Jung Han, Sung-Ik Lee, Sung-Hye Park, Wongi Seol, Ilhong Son, Dong Hwan Ho
Publikováno v:
Animal Cells and Systems, Vol 25, Iss 1, Pp 28-36 (2021)
Research on Parkinson’s disease (PD) has been focused on the development of PD diagnostic tools as much as the development of PD therapeutics. Several genetic culprits of PD, including DJ-1, Leucine-rich repeat kinase 2 (LRRK2), and α-synuclein (
Externí odkaz:
https://doaj.org/article/c3461cdab30c4d8c957e3011100640b4
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 3, p 2132 (2023)
α-Synuclein (αSyn) is an important player in Parkinson’s disease (PD) pathogenesis. The aggregation of αSyn is mainly formed in the cytoplasm, whereas some αSyn accumulation has also been found in the nuclei of neurons. To assess the effect of
Externí odkaz:
https://doaj.org/article/72b3a2c50e6f47019861ed7ddcd4d055
Publikováno v:
Neurobiology of Disease, Vol 154, Iss , Pp 105349- (2021)
Alpha-synuclein (αSyn) is a major component of Lewy bodies, which are a known pathogenic marker of Parkinson's disease (PD). The dysfunction of protein degradation machinery causes αSyn accumulation. The reinforcement of αSyn degradation is a pote
Externí odkaz:
https://doaj.org/article/9c7772b717c54bc1ba91bc855cc3386b
Autor:
Muhack Yang, Seongjin Lee, Tingting Wang, Eunhye Cha, Jongwon Jang, Dongwoung Kim, Bong-Keun Song, Ilhong Son, Joonyup Kim, Hyung Won Kang, Sungchul Kim
Publikováno v:
Journal of Pharmacopuncture, Vol 22, Iss 3, Pp 192-199 (2019)
Objectives: KCHO-1(Mecasin), also called Gamijakyakgamchobuja-tang originally, is a combination of some traditional herbal medicines in East Asia. This medicine has been used mainly for alleviating neuropathic pains for centuries in Korean traditiona
Externí odkaz:
https://doaj.org/article/443347f888b443128efd6b460cb6feb3
Publikováno v:
Animal Cells and Systems, Vol 23, Iss 2, Pp 106-111 (2019)
Leucine rich-repeat kinase 2 (LRRK2) is involved in the pathogenesis of Parkinson’s disease (PD). LRRK2 has kinase and GTPase activities, and mediates several cell functions, including vesicle trafficking, apoptosis, autophagy, mitochondrial dynami
Externí odkaz:
https://doaj.org/article/6d5d11ba2e3046a58ddb71bc8e86fbd7
Publikováno v:
Cells, Vol 11, Iss 5, p 861 (2022)
Evidence suggests that crosstalk occurs between microglial leucine-rich repeat kinase 2 (LRRK2)—a regulator of neuroinflammation—and neuron-released α-synuclein (αSyn)—a promoter of microglial activation and neuroinflammatory responses—in n
Externí odkaz:
https://doaj.org/article/ad893a6a11b54c1791b6970305e85286
Autor:
Jihoon Jang, Hakjin Oh, Daleum Nam, Wongi Seol, Mi Kyoung Seo, Sung Woo Park, Hyung Gun Kim, Hyemyung Seo, Ilhong Son, Dong Hwan Ho
Publikováno v:
Animal Cells and Systems, Vol 22, Iss 5, Pp 273-280 (2018)
Leucine-rich repeat kinase 2 (LRRK2) is involved in Parkinson’s disease (PD) pathology. A previous study showed that rotenone treatment induced apoptosis, mitochondrial damage, and nucleolar disruption via up-regulated LRRK2 kinase activity, and th
Externí odkaz:
https://doaj.org/article/9feb4789e01948629aca6824ea330f2e
Autor:
Sungha Kim, Jae Kyoun Kim, Mi Ju Son, Dongwoung Kim, Bongkeun Song, Ilhong Son, Hyung Won Kang, Jongdeok Lee, Sungchul Kim
Publikováno v:
Trials, Vol 19, Iss 1, Pp 1-8 (2018)
Abstract Background Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that causes paralysis of limb, swallowing, and breathing muscles. Riluzole, the Food and Drug Administration-approved drug for ALS, provides minimal benefit,
Externí odkaz:
https://doaj.org/article/51a44335b699466c9019d07c6c188925